menu
    • menu
    [{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mescaline","moa":"5-HT2A receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Journey Colab","sponsor":"MBX Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Mescaline","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Journey Colab","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Journey Colab \/ MBX Capital","highestDevelopmentStatusID":"4","companyTruncated":"Journey Colab \/ MBX Capital"}]

    Find Clinical Drug Pipeline Developments & Deals for Mescaline

    Menu

    Mescaline

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Biomind Labs

    Canada arrow
    Interphex
    Not Confirmed

    Biomind Labs

    Canada arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Mescaline

    Therapeutic Area : Immunology

    Study Phase : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Biomind Labs to Commence Commercial Clinical Trial on Its Proprietary Mescaline Candidate BMND06

    Details :

    Product Name : BMND06

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    March 24, 2022

    Lead Product(s) : Mescaline

    Therapeutic Area : Immunology

    Highest Development Status : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Journey Colab

    U.S.A arrow
    Interphex
    Not Confirmed

    Journey Colab

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Mescaline

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Preclinical

    Sponsor : MBX Capital

    Deal Size : $12.0 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    Journey Colab Secures $12 M Series A Funding for Phase 1 Trial of Mescaline H Cl (jour-001) for Treatment of A...

    Details : The funding will be used to accelerate the development of Journey Colab’s portfolio of psychedelic compounds. Journey Colab’s lead compound, Mescaline HCl (JOUR-001), is being developed for the treatment of Alcohol Use Disorder (AUD).

    Product Name : JOUR-001

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    July 09, 2021

    Lead Product(s) : Mescaline

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Preclinical

    Sponsor : MBX Capital

    Deal Size : $12.0 million

    Deal Type : Series A Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth